ijms-logo

Journal Browser

Journal Browser

Protein Methyltransferases in Human Health and Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 30 July 2025 | Viewed by 2856

Special Issue Editor


E-Mail Website
Guest Editor
Centre for Molecular Medicine and Biobanking, University of Malta, MSD2080 Msida, Malta
Interests: proteomics; functional biochemistry; post-translational modifications; lysine methylation; mass spectrometry; cancer diagnostics

Special Issue Information

Dear Colleagues,

A wide variety of methyltransferases add methylations to proteins in key regulatory pathways, which are spatially, temporally, and chemically dynamic. Despite the abundance of these post-translational modifications (PTM) in the human proteome, our understanding of the role of most of these methyltransferase enzymes in cellular biology and disease is still limited. This has a particularly significant impact on cancer and neurodegenerative diseases, where novel treatment strategies are being sought.

Moreover, in relation to the different methyltrasnsferase enzyme families, the degree of methylation adds an extra layer of complexity, since lysine can undergo mono- (Kme1), di- (Kme2), or tri- (Kme3) methylation, while arginine can undergo mono- (Rme1), di-symetrical (sRme2), and di-asymmetrical (aRme2) methylation, and these are sometimes performed by different enzymes at one specific residue. The addition of this PTM leads to some sort of change in protein properties, which consequently, either directly or indirectly, impacts the function via domain activity, interaction strength to target proteins or DNA, localization, and protein stability or half-life. Moreover, methylation can crosstalk or compete with other PTMs, adding another layer of regulation. For this reason, protein methylation is gaining interest for diagnostic and prognostic applications, particularly on lysines and arginines in non-histone proteins. The dysregulation of protein methyltransferases has also been implicated in disease, making such enzymes potential therapeutic targets, for which there are only few inhibiting small molecules that are in clinical trials. However, despite recognizing the importance of methyltransferase enzymes in both cellular biology and human disease, much is still unknown regarding their full complement of target proteins, modified residue positions, degree, and function. The main reasons for this are a lack of reliable tools and methods for studying these modifications.

This Special Issue aims to gather any advances in relation to the protein methyltransferase enzymes. Topics include, but are not limited to:

  • Identification of protein methyltransferases as biomarkers in diagnostics or therapeutics;
  • Identification of pathways or contexts in which protein methyltransferases are involved;
  • Testing of novel protein methyltransferase inhibitors for controlling disease progression.

Dr. Byron Baron
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lysine and arginine methylation
  • mass spectrometry
  • PTM cross talk
  • functional proteomics
  • cancer
  • neurological disorders

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

25 pages, 2435 KiB  
Review
Role of PRMT1 and PRMT5 in Breast Cancer
by Sébastien Martinez, Stéphanie Sentis, Coralie Poulard, Olivier Trédan and Muriel Le Romancer
Int. J. Mol. Sci. 2024, 25(16), 8854; https://doi.org/10.3390/ijms25168854 - 14 Aug 2024
Cited by 2 | Viewed by 2303
Abstract
Breast cancer is the most common cancer diagnosed in women worldwide. Early-stage breast cancer is curable in ~70–80% of patients, while advanced metastatic breast cancer is considered incurable with current therapies. Breast cancer is a highly heterogeneous disease categorized into three main subtypes [...] Read more.
Breast cancer is the most common cancer diagnosed in women worldwide. Early-stage breast cancer is curable in ~70–80% of patients, while advanced metastatic breast cancer is considered incurable with current therapies. Breast cancer is a highly heterogeneous disease categorized into three main subtypes based on key markers orientating specific treatment strategies for each subtype. The complexity of breast carcinogenesis is often associated with epigenetic modification regulating different signaling pathways, involved in breast tumor initiation and progression, particularly by the methylation of arginine residues. Protein arginine methyltransferases (PRMT1-9) have emerged, through their ability to methylate histones and non-histone substrates, as essential regulators of cancers. Here, we present an updated overview of the mechanisms by which PRMT1 and PRMT5, two major members of the PRMT family, control important signaling pathways impacting breast tumorigenesis, highlighting them as putative therapeutic targets. Full article
(This article belongs to the Special Issue Protein Methyltransferases in Human Health and Diseases)
Show Figures

Figure 1

Back to TopTop